防风通圣颗粒联合奥司他韦治疗普通型病毒性肺炎的临床研究  

Clinical study of Fangfeng Tongsheng Granules combined with oseltamivir in treatment of common viral pneumonia

作　　者：栾相佳[1] 姚晓燕[2] 李萌[2] 刘志国[2] 张金枝 夏宏盛 尹建坤 LUAN Xiang-jia;YAO Xiao-yan;LI Meng;LIU Zhi-guo;ZHANG Jin-zhi;XIA Hong-sheng;YIN Jian-kun(Department of Geriatrics,Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Department of Respiratory,Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Beijing University of Traditional Chinese Medicine,Beijing 100029,China)

机构地区：[1]中国中医科学院广安门医院老年病科,北京100053 [2]中国中医科学院广安门医院呼吸科,北京100700 [3]北京中医药大学,北京100029

出　　处：《现代药物与临床》2022年第11期2534-2538,共5页Drugs & Clinic

摘　　要：目的探讨防风通圣颗粒联合奥司他韦治疗普通型病毒性肺炎的临床疗效。方法选取2020年3月—2021年4月中国中医科学院广安门医院收治的92例普通型病毒性肺炎患者,按随机数字表法将所有患者分为对照组和治疗组,每组各46例。对照组口服磷酸奥司他韦胶囊,75 mg/次,2次/d。治疗组在对照组基础上温水冲服防风通圣颗粒,3 g/次,2次/d,当腋下体温>37.3℃时用药剂量调整为6 g/次,2次/d。两组疗程7 d。观察两组疗效,比较治疗前后两组典型症状评分、临床肺部感染评分(CPIS)、肺炎胸片吸收评价量表评分以及血清程序性细胞死亡因子5(PDCD5)、C反应蛋白(CRP)、高迁移率族蛋白B1(HMGB1)、白细胞介素(IL)-1β水平。结果治疗后,治疗组总有效率是95.65%,显著高于对照组的82.61%(P<0.05)。治疗后,两组患者发热评分、日间咳嗽评分、夜间咳嗽评分、咯痰评分、胸闷痛评分均较治疗前显著降低(P<0.05),治疗后,治疗组典型症状评分低于对照组(P<0.05)。治疗后,两组CPIS评分、肺炎胸片吸收评价量表评分均较治疗前显著降低(P<0.05);治疗后,治疗组CPIS评分、肺炎胸片吸收评价量表评分显著低于对照组(P<0.05)。治疗后,两组血清PDCD5、CRP、HMGB1、IL-1β水平均显著低于治疗前(P<0.05);且治疗后,治疗组血清PDCD5、CRP、HMGB1、IL-1β水平均显著低于对照组(P<0.05)。结论防风通圣颗粒联合奥司他韦治疗普通型病毒性肺炎有确切疗效,能明显改善患者肺炎典型症状,减轻肺部感染程度,并能有效抑制机体细胞凋亡以及炎症反应,利于病情缓解,且安全性较好,具有一定的临床推广应用价值。Objective To investigate the clinical efficacy of Fangfeng Tongsheng Granules combined with oseltamivir in treatment of common viral pneumonia. Methods A total of 92 patients with common viral pneumonia admitted to Guang’anmen Hospital of China Academy of Chinese Medical Sciences from March 2020 to April 2021 were selected. All patients were divided into control group and treatment group according to the random number table method, with 46 cases in each group. Patients in the control group were po administered with Oseltamivir Phosphate Capsules, 75 mg/time, twice daily. Patients in the treatment group were po administered with Fangfeng Tongsheng Granules with warm water on the basis of the control group, 3 g/time, twice daily, and the dose was adjusted to 6 g/time, twice daily when the armpit temperature was higher than 37.3 ℃. The treatment course of the two groups was 7 d. The efficacy of the two groups was observed. The typical symptom score, clinical pulmonary infection score(CPIS),pneumonia chest radiograph absorption assessment scale score, and serum programmed cell death factor 5(PDCD5), C-reactive protein(CRP), high mobility group B1(HMGB1), interleukin-1β levels were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 95.65%, which was significantly higher than 82.61% of the control group(P < 0.05). After treatment, the scores of fever, daytime cough, night cough, sputum cough and chest pain in the two groups were significantly lower than those before treatment(P < 0.05). After treatment, the scores of typical symptoms in the treatment group were lower than those in the control group(P < 0.05). After treatment, the CPIS score and the Pneumonia chest Radiograph absorption assessment scale score of the two groups were significantly lower than those before treatment(P < 0.05). After treatment, the CPIS score and the pneumonia chest radiograph absorption assessment scale score of the treatment group were significantly

关 键 词：防风通圣颗粒 磷酸奥司他韦胶囊 普通型病毒性肺炎 程序性细胞死亡因子5 炎症反应 

分 类 号：R974[医药卫生—药品]